Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

238 - To assess the pain control and tolerance to drug induced emesis in oral and neck carcinoma patients undergoing chemoradiation treated for pain relief with tapentadol (TAPAL -ER 50) vs. tramadol plus paracetamol with and without anti-emetic support


05 Mar 2018


Poster display


Rajesh Narayanasamy


Annals of Oncology (2018) 29 (suppl_3): iii10-iii34. 10.1093/annonc/mdy047


R. Narayanasamy

Author affiliations

  • Radiation Oncology, Rai CBCC Cancer Center, 600095 - Chennai/IN


Abstract 238

Pain control in oral and neck carcinoma patients treated with chemoradiation are a challenge to manage, achieving a pain control and avoiding the complication of pain killers is as more important as pain control. In this study locally advanced squamous cell carcinoma treated with concurrent chemo radiation involving inj cisplatin for all patients and few patients were given inj nimotuzumab along with inj cisplatin. Controlling pain for moderate- severe level with tramadol without antiemetics is not tolerated by most of the patients, adding a drug for a drug induced complication (emesis) is a burden for patients, hence drug with least complication is always better.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings